US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Cabaletta Bio
< Previous
1
2
Next >
Cabaletta Bio to Participate in Upcoming Investor Conferences
September 01, 2026
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
June 03, 2026
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
May 14, 2026
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
May 04, 2026
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
April 28, 2026
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
April 27, 2026
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 23, 2026
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 05, 2026
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces 2026 Strategic Priorities
January 12, 2026
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
November 10, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
November 04, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
October 27, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
October 14, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
October 09, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
August 27, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
August 07, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces Pricing of Public Offering of Securities
June 11, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces Proposed Public Offering of Securities
June 11, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
June 11, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
May 29, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
May 15, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 31, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
February 26, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
February 18, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
February 18, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
February 11, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
January 29, 2025
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
< Previous
1
2
Next >
